

Fragile X Syndrome-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/F1859635E89EN.html>

Date: February 2018

Pages: 141

Price: US\$ 2,480.00 (Single User License)

ID: F1859635E89EN

Abstracts

Report Summary

Fragile X Syndrome-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Fragile X Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Fragile X Syndrome 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Fragile X Syndrome worldwide, with company and product introduction, position in the Fragile X Syndrome market

Market status and development trend of Fragile X Syndrome by types and applications

Cost and profit status of Fragile X Syndrome, and marketing status

Market growth drivers and challenges

The report segments the global Fragile X Syndrome market as:

Global Fragile X Syndrome Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Fragile X Syndrome Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others

Global Fragile X Syndrome Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic
Hopital
Research Center

Global Fragile X Syndrome Market: Manufacturers Segment Analysis (Company and Product introduction, Fragile X Syndrome Sales Volume, Revenue, Price and Gross Margin):

Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and

individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF FRAGILE X SYNDROME

- 1.1 Definition of Fragile X Syndrome in This Report
- 1.2 Commercial Types of Fragile X Syndrome
 - 1.2.1 ACT-01
 - 1.2.2 AMO-01
 - 1.2.3 ANAVEX-273
 - 1.2.4 AUT-00206
 - 1.2.5 Bryostatin-1
 - 1.2.6 Cannabidiol
 - 1.2.7 Others
- 1.3 Downstream Application of Fragile X Syndrome
 - 1.3.1 Clinic
 - 1.3.2 Hopital
 - 1.3.3 Research Center
- 1.4 Development History of Fragile X Syndrome
- 1.5 Market Status and Trend of Fragile X Syndrome 2013-2023
 - 1.5.1 Global Fragile X Syndrome Market Status and Trend 2013-2023
 - 1.5.2 Regional Fragile X Syndrome Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Fragile X Syndrome 2013-2017
- 2.2 Production Market of Fragile X Syndrome by Regions
 - 2.2.1 Production Volume of Fragile X Syndrome by Regions
 - 2.2.2 Production Value of Fragile X Syndrome by Regions
- 2.3 Demand Market of Fragile X Syndrome by Regions
- 2.4 Production and Demand Status of Fragile X Syndrome by Regions
 - 2.4.1 Production and Demand Status of Fragile X Syndrome by Regions 2013-2017
 - 2.4.2 Import and Export Status of Fragile X Syndrome by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Production Volume of Fragile X Syndrome by Types
- 3.2 Production Value of Fragile X Syndrome by Types
- 3.3 Market Forecast of Fragile X Syndrome by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Fragile X Syndrome by Downstream Industry

4.2 Market Forecast of Fragile X Syndrome by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF FRAGILE X SYNDROME

5.1 Global Economy Situation and Trend Overview

5.2 Fragile X Syndrome Downstream Industry Situation and Trend Overview

CHAPTER 6 FRAGILE X SYNDROME MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

6.1 Production Volume of Fragile X Syndrome by Major Manufacturers

6.2 Production Value of Fragile X Syndrome by Major Manufacturers

6.3 Basic Information of Fragile X Syndrome by Major Manufacturers

6.3.1 Headquarters Location and Established Time of Fragile X Syndrome Major Manufacturer

6.3.2 Employees and Revenue Level of Fragile X Syndrome Major Manufacturer

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 FRAGILE X SYNDROME MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Aelis Farma SAS

7.1.1 Company profile

7.1.2 Representative Fragile X Syndrome Product

7.1.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Aelis Farma SAS

7.2 Alcobra Ltd

7.2.1 Company profile

7.2.2 Representative Fragile X Syndrome Product

7.2.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Alcobra Ltd

7.3 AMO Pharma Limited

7.3.1 Company profile

- 7.3.2 Representative Fragile X Syndrome Product
- 7.3.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of AMO Pharma Limited
- 7.4 Confluence Pharmaceuticals LLC
 - 7.4.1 Company profile
 - 7.4.2 Representative Fragile X Syndrome Product
 - 7.4.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Confluence Pharmaceuticals LLC
- 7.5 Eli Lilly and Company
 - 7.5.1 Company profile
 - 7.5.2 Representative Fragile X Syndrome Product
 - 7.5.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
- 7.6 F. Hoffmann-La Roche Ltd.
 - 7.6.1 Company profile
 - 7.6.2 Representative Fragile X Syndrome Product
 - 7.6.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.7 Marinus Pharmaceuticals, Inc.
 - 7.7.1 Company profile
 - 7.7.2 Representative Fragile X Syndrome Product
 - 7.7.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Marinus Pharmaceuticals, Inc.
- 7.8 MI.TO. Technology S.r.L.
 - 7.8.1 Company profile
 - 7.8.2 Representative Fragile X Syndrome Product
 - 7.8.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of MI.TO. Technology S.r.L.
- 7.9 Neuren Pharmaceuticals Limited
 - 7.9.1 Company profile
 - 7.9.2 Representative Fragile X Syndrome Product
 - 7.9.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Neuren Pharmaceuticals Limited
- 7.10 Ovid Therapeutics Inc.
 - 7.10.1 Company profile
 - 7.10.2 Representative Fragile X Syndrome Product
 - 7.10.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Ovid Therapeutics Inc.
- 7.11 Sage Therapeutics, Inc.

- 7.11.1 Company profile
- 7.11.2 Representative Fragile X Syndrome Product
- 7.11.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Sage Therapeutics, Inc.
- 7.12 Zynerva Pharmaceuticals, Inc.
 - 7.12.1 Company profile
 - 7.12.2 Representative Fragile X Syndrome Product
 - 7.12.3 Fragile X Syndrome Sales, Revenue, Price and Gross Margin of Zynerva Pharmaceuticals, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF FRAGILE X SYNDROME

- 8.1 Industry Chain of Fragile X Syndrome
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF FRAGILE X SYNDROME

- 9.1 Cost Structure Analysis of Fragile X Syndrome
- 9.2 Raw Materials Cost Analysis of Fragile X Syndrome
- 9.3 Labor Cost Analysis of Fragile X Syndrome
- 9.4 Manufacturing Expenses Analysis of Fragile X Syndrome

CHAPTER 10 MARKETING STATUS ANALYSIS OF FRAGILE X SYNDROME

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Fragile X Syndrome-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/F1859635E89EN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F1859635E89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970